LONDON (Alliance News) - Summit Therapeutics PLC on Friday said it will present new positive data on its SMT19969 drug for the treatment of Clostridium difficile infection at the 55th Interscience Conference on Antimicrobial Agents and Chemotherapy in San Diego.
The data has been collated from pre-clinical in vitro studies which provide further evidence to support the profile of the product for treating CDI and the ability it has to reduce recurrence rates of the disease.
"These new data further illustrate the promise of SMT19969 as a differentiated antibiotic to treat CDI and, through its selective antibiotic profile, potential to leave the healthy gut microbiome unharmed, and so address the key clinical issue of disease recurrence," said Glyn Edwards, Summit's chief executive.
"It is an exciting time in the development of SMT19969 as we look forward to reporting top-line data from our Phase 2 proof of concept trial during the fourth quarter of this year," he added.
Summit shares were up 0.7% to 155.00 pence on Friday.
By Sam Unsted; samunsted@alliancenews.com; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.
